Pamidronic acid/zoledronic acid
- PDF / 141,592 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 18 Downloads / 192 Views
1
Pamidronic acid/zoledronic acid Jaw osteonecrosis: 4 case reports Four patients, who had multiple myeloma (patients 1 and 2) and breast cancer (patients 3 and 4) developed jaw osteonecrosis during treatment with zoledronic acid [see table]; patients 2 and 3 had also received pamidronic acid before zoledronic acid initiation.
Patient characteristics Patient
Age (years)/sex
Drugs
Time to reaction onset (months)
1 2
57/F 56/M
3 4
35/F 45/F
Zoledronic acid Pamidronic acid Zoledronic acid Zoledronic acid Pamidronic acid Zoledronic acid
28 59 16 18 35 33
All patients were receiving zoledronic acid 4 mg/month and chemotherapy when they developed jaw osteonecrosis; patients 2 and 3 had also received pamidronic acid 90 mg/month before zoledronic acid initiation. All patients presented with jaw pain and duration of treatment before presentation ranged from 18 to 75 months. Patients 1, 2 and 4 developed osteonecrosis at the sites of nonhealing dental extraction. Osteonecrosis was unilateral and localised to mandible (patients 1 3 and 4) and maxilla (patient 2). Biopsy findings in all patients confirmed osteonecrosis. In all patients, bisphosphonates were discontinued and treatment with antibacterials and chlorhexidine mouthwash was initiated. All patients also underwent minor debridement; patient 2 also received hyperbaric oxygen. Symptoms had relieved in all patients at a follow-up between 19 and 29 months. Kanat O, et al. Bisphosphonate tratment as a cause of jaw osteonecrosis. Oral 801078025 Diseases 13: 346-347, No. 3, May 2007 - Turkey
0114-9954/10/1160-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 14 Jul 2007 No. 1160
Data Loading...
